Series by David C. Helfgott, MD
A collection of news, case studies, and feature articles focused on the diagnosis and management of infectious processes in patients with immune systems impaired by an underlying disease, such as hematologic malignancies that affect cells crucial to normal host immune response, or weakened secondary to treatments for disease, such as steroids, chemotherapeutic agents, or biologic response modifiers targeting immune mediators.
In this review, David C. Helfgott, MD, editorial advisory board member for Infectious Disease Advisor, focuses on infectious complications from the use of monoclonal antibodies for malignancy.
The risk for infection and malignancy associated with biologic use complicates the management of patients with a deficient immune system. Equip yourself with the information needed to effectively manage these complex patients.
September 15, 2017
Case of a 51-year-old man with Crohn's disease who develops fever and cough after receiving biologic treatment.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- New AAP Policy on Patient Dismissal for Vaccine Refusal May "Erode Solidarity" Among Pediatricians
- Increasing Incidence of Syphilis in People With HIV
- FDA: Possible Risk of Neural Tube Birth Defects With Certain Antiretroviral Agents
- Fungal Infections of the CNS: Diagnostic and Treatment Approaches
- Study Supports Development of a Vaccine for Recurrent Vulvovaginal Candidiasis
- Early Flow Cytometry Predictive of Clinical Deterioration in Sepsis
- Could a New Universal Tuberculosis Regimen Help End the TB Pandemic?
- Hepatitis C Virus Infection Linked to Gut Dysbiosis
- Two Hepatitis C Virus Infection Treatments to Be Discontinued
- Antibiotic Use During Pregnancy May Increase Risk for Childhood Asthma